Epidemiology of Human T-Lymphotropic Virus Type III and the Risk of the Acquired Immunodeficiency Syndrome

  1. WILLIAM A. BLATTNER, M.D.;
  2. ROBERT J. BIGGAR, M.D.;
  3. STANLEY H. WEISS, M.D.;
  4. MADS MELBYE, M.D.; and
  5. JAMES J. GOEDERT, M.D.
  1. Bethesda, Maryland; and Aarhus, Denmark

    Abstract

    The discovery of human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) has opened a window to the understanding of the spectrum of the acquired immunodeficiency syndrome (AIDS) and related clinical syndromes. Analysis of risk factors for seropositivity has shown that HTLV-III is transmitted most efficiently via routes that involve close personal contact or parenteral exposure. Longitudinal studies have shown that HTLV-III infection has a long latent period. The prevalence of AIDS in different geographic areas and among different risk groups appears to depend in part on duration of exposure. Co-factors for AIDS outcome such as manner and route of exposure, underlying immune status, and host susceptibility are also likely to play a role in risk.

    Article and Author Information

    • ▸From the Environmental Epidemiology Branch, National Cancer Institute, Bethesda, Maryland; and the Institute of Cancer Research, Aarhus, Denmark.

    • ▸Requests for reprints should be addressed to William A. Blattner, M.D.; Environmental Epidemiology Branch, National Cancer Institute, Landow Building, Room 3C25; Bethesda, MD 20205.

    « Previous | Next Article »Table of Contents